Sign In
Buy ACHV
$4.92
-0.110 (-2.19%)
At Close: Jun 03, 2026
Achieve Life Sciences: FDA Approval Not Assured, But Valuation Justifies Risk
06:28pm, Tuesday, 03'rd Jun 2025
Achieve Life Sciences (ACHV) is positioned for growth with its lead smoking cessation therapy, cytisinicline, advancing through late-stage clinical trials. The company addresses a significant unmet ne
Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference
08:30am, Wednesday, 28'th May 2025
SEATTLE and VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage specialty pharmaceutical company focused on the global development an
SEATTLE and VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV) a late-stage specialty pharmaceutical company focused on the global development and
Achieve Life Sciences, Inc. (ACHV) Q1 2025 Earnings Call Transcript
12:16pm, Tuesday, 13'th May 2025
Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Nicole Jones - Investor Relations Rick Stewart - Chief Executive Officer Cindy
Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program
07:30am, Tuesday, 13'th May 2025
Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, May 13, 2025 SEATTLE and VANCOUVER, British Columbia, May 1
Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025
08:30am, Tuesday, 06'th May 2025
SEATTLE and VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV) a late-stage specialty pharmaceutical company focused on the global development and
Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine
11:19am, Monday, 21'st Apr 2025
ORCA-3 Demonstrated a Significant Increase in Quitting and Reduction in Nicotine Cravings for Cytisinicline-Treated Participants Compared to Placebo
Achieve Life Sciences, Inc. (ACHV) Q4 2024 Earnings Call Transcript
02:52pm, Tuesday, 11'th Mar 2025
Achieve Life Sciences, Inc. (NASDAQ:ACHV ) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Nicole Jones - IR Richard Stewart - Chief Executive Officer Cindy Jacobs - Pr
Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, March 11, 2025 SEATTLE and VANCOUVER, British Columbia, Ma
Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference
08:30am, Friday, 07'th Mar 2025
SEATTLE and VANCOUVER, British Columbia, March 07, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development
SEATTLE and VANCOUVER, British Columbia, March 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development
Achieve Life Sciences to Present at the Oppenheimer Healthcare Life Sciences Conference
08:30am, Tuesday, 11'th Feb 2025
SEATTLE and VANCOUVER, British Columbia, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development
No Safety Concerns Identified by DSMC in the ORCA-OL Long-Term Exposure Trial Achieve Reiterates Planned Cytisinicline NDA Submission in Q2 2025 SEATTLE and VANCOUVER, British Columbia, Feb. 10, 2025
Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors
08:30am, Friday, 10'th Jan 2025
New Directors Bring Extensive Leadership Experience in Corporate Strategy and Commercialization New Directors Bring Extensive Leadership Experience in Corporate Strategy and Commercialization
Over 300 Participants Have Completed Cumulative Six Months of Cytisinicline Treatment in the ORCA-OL Trial, Completing the Long-Term Exposure Requirement for NDA Submission
